PRIAS
Prostate cancer Research International: Active surveillance

Inclusion criteria:
1) Histologically proven adenocarcinoma of the prostate.
2) Men should be fit for curative treatment.
3) PSA-level at diagnosis ≤ 10 ng/mL.
4) PSA density (PSA D) less than 0.2 ng/ml/ml.
5) Clinical stage T1C or T2.
6) Gleason score 3+3=6.
7) One or 2 biopsy cores invaded with prostate cancer.
   a. If an MRI, including targeted biopsies on positive lesions, is done at inclusion, there is no limit in the number of positive cores (that is, more than two, and no limit in the % of cancer present in the cores).
   b. If saturation biopsies (either transperineal or transrectal) are done 15% of the cores can be positive with a maximum of 4. (i.e. <20 cores 2 cores can be positive (standard), 20-26 cores 3 cores can be positive, >26 cores 4 cores can be positive) (all other inclusion criteria still apply).
8) Participants must be willing to attend the follow-up visits.
9) Adequate biopsy sampling:

<table>
<thead>
<tr>
<th>Prostatic volume (cc)</th>
<th>Number of biopsy cores</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-40</td>
<td>8</td>
</tr>
<tr>
<td>40-60</td>
<td>10</td>
</tr>
<tr>
<td>&gt; 60</td>
<td>12</td>
</tr>
</tbody>
</table>

Exclusion criteria:
1) Men who cannot or do not want to be radiated or operated.
2) A former therapy for prostate cancer.

Questions: www.prias-project.org